Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
peptide
GLP-1 receptor agonist |
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvedBy |
gptkb:type_2_diabetes_mellitus
|
| gptkbp:associatedWith |
gptkb:exenatide
|
| gptkbp:discoveredIn |
1992
|
| gptkbp:foundIn |
Gila monster venom
|
| gptkbp:halfLife |
2.4 hours
|
| gptkbp:hasMolecularFormula |
C184H282N50O60S
|
| https://www.w3.org/2000/01/rdf-schema#label |
exendin-4
|
| gptkbp:length |
39 amino acids
|
| gptkbp:marketedAs |
gptkb:Bydureon
gptkb:Byetta |
| gptkbp:mechanismOfAction |
slows gastric emptying
stimulates insulin secretion suppresses glucagon secretion |
| gptkbp:origin |
gptkb:Heloderma_suspectum
|
| gptkbp:proteinFamily |
incretin mimetic
|
| gptkbp:relatedTo |
glucagon-like peptide-1 (GLP-1)
|
| gptkbp:sequenceSimilarity |
gptkb:GLP-1
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea hypoglycemia (with sulfonylureas) |
| gptkbp:structureType |
peptide
|
| gptkbp:usedFor |
treatment of type 2 diabetes
|
| gptkbp:bfsParent |
gptkb:exenatide
|
| gptkbp:bfsLayer |
7
|